Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Someone

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Apr 14, 2022 8:50pm

111 Views

Post# 34605745

RE:RE:RE:RE:Someone

Chianchin wrote: Mr madmugsy, I can certailnly and easly calculate you financial disaster. You have been pedling ATE and GUD for eight Years. If indeed you had invested one $1dollar for each, ATE & GUD you $2 two dollars 8 years ago is now worth .45 cents . Bad very bad investor you are.

Come on Chi-chi ... let's put aside our differences and get cozy by the fire - just you and me.

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia